Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Lee M. Greenberger,1,4 Larry A. Saltzman,1 Jonathon W. Senefeld,2 Patrick W. Johnson,3 Louis J. DeGennaro,1 and Gwen L. Nichols1

1The Leukemia & Lymphoma Society, Rye Brook, NY, USA
2Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA
3Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL
4Correspondence: lee.greenberger@lls.org

It has been reported that ~15%-25% of patients with hematologic malignancies fail to make anti-spike (anti-S) antibodies in response to full dosing of SARS-CoV-2 mRNA vaccines (Greenberger et al., 2021; Griffiths and Segal, 2021). Patients with B cell malignancies are at the highest risk of not making anti-S antibodies. Although the complete immune response in B and T cells is not fully understood, these findings suggest that seronegative patients may be vulnerable to breakthrough infections. Patients with B cell malignancies are of particular concern because, in the pre-vaccine period of the pandemic, some patients with blood cancer who contracted COVID-19 had prolonged, severe infections; generated variant strains (Corey et al., 2021); and demonstrated significantly higher mortality rates compared to the general population (Bakouny et al., 2020; Vjen-thira et al., 2020).

In a recent placebo-controlled trial, booster vaccination mediated an increase in anti-S antibodies and neutralizing antibodies in immunosuppressed patients who had solid organ transplantation (Hall et al., 2021). On August 12, 2021, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization for the mRNA vaccines (BNT162b2 and mRNA-1273) to allow the use of a booster dose for immuno-compromised people. We report here the antibody responses to booster vaccination obtained prior to FDA authorization in 49 patients with B cell-derived hematologic malignancies.

As described previously (Greenberger et al., 2021), we used a prospective national registry (The Leukemia & Lymphoma Society National Registry; https://www.citizen.com/lls/; NCT04794387) to assess the serologic response to vaccinations against SARS-CoV-2. The semiquantitative Elecsys Anti-SARS-CoV-2 S enzyme immunoassay (Roche) for the detection of IgG anti-S1-RBD-SARS-CoV-2 was used with a positive cutoff of at least 0.8 AU/mL and a maximum range of 2,500 AU/mL. These assay readouts correlate with neutralizing immunity mediated by vaccination (Resman Rus et al., 2021). It has also been shown recently that both the semiquantitative anti-S antibody and neutralizing levels are inversely correlated with the risk of COVID-19 infections using data from a 30,000-patient trial with the mRNA-1273 SARS-CoV-2 vaccine (Gilbert et al., 2021).

An assessment of anti-S antibody levels was done 27 days (median value, range 1–99 days) before and 28 days (median value, range 12–61 days) after the booster vaccination (Figure S1). There were no restrictions on initial or booster vaccine type. Patients who were nucleocapsid positive before or after the booster vaccination were excluded from the analysis. Only patients who had enrolled in the registry prior to booster vaccination were included in this study. This study was approved by the Western Institutional Review Board, and participants provided informed consent electronically.

Our cohort was composed of 49 patients with B cell malignancies: 25 patients with chronic lymphocytic leukemia (CLL), 18 patients with non-Hodgkin Lymphoma (NHL) including 7 patients with Waldenstrom’s macroglobulinemia (WM), 4 patients with multiple myeloma (MM), 1 patient with CLL and marginal zone lymphoma, and 1 patient with Epstein-Barrvirus-associated lymphopro-
2,128 AU/mL (interquartile range, 563.5–1,458.5 AU/mL).

Although examining subgroupings stratified by disease type or malignancy-targeted therapies was not the primary focus, our previous findings suggest that both disease and therapies can affect the serological response to vaccination (Greenberger et al., 2021). Among the 12 patients who received no malignancy-targeted treatments in the past 2 years, only 1 patient (#14) was a non-responder, 7 patients (#23, #26, #28, #29, #33, #34, and #37) demonstrated seroconversion, and 4 patients (#44, #45, #47, and #48) demonstrated sero-elevation. In contrast, among the 21 patients who completed therapy with anti-CD20 antibodies either alone or in combination with other therapies, 12 patients were non-responders, 7 patients demonstrated seroconversion, and 2 patients demonstrated sero-elevation. Notably, 5 of the 7 patients who completed therapy with anti-CD20 antibodies alone or in combination with chemotherapy at least 7 months prior to the booster vaccination demonstrated seroconversion (patients #22, #25, #27, and #32) or sero-elevation (patient #40). In contrast, many of the patients who recently had, or are maintained on, anti-CD20 antibody therapy prior to booster vaccination failed to seroconvert after booster vaccination. It has previously been reported that recovery of B cells begins 6–9 months after rituximab therapy (McLaughlin et al., 1998). Thus, these data suggest that recent treatment regimens containing anti-CD20 antibodies may suppress the response to booster vaccination.

The use of a Bruton tyrosine kinase inhibitor (BTKi) has been shown to be correlated with a lack of response to vaccination (Greenberger et al., 2021; Griffiths and Segal, 2021). Among the patients who experienced sero-elevation and were treated with a BTKi, 2 patients (#43 and #49) discontinued BTKi therapy 7–23 months prior to booster vaccination, 1 patient (#41) maintained a low dose of ibrutinib prior to booster vaccination, and 1 patient (#42) maintained BTKi therapy continuously before and after the booster vaccination. In addition, the 2 patients (#36 and #38) who experienced marked seroconversion after booster vaccination (an increase of over 1,000 AU/mL) stopped BTKi therapy at least 4 months before the booster vaccination. In comparison, 5 patients (#18, #19, #20, #21, and #24) who had very weak seroconversion (an increase of 2.2–5.2 AU/mL) and 2 patients (#30 and #31) who had moderate seroconversion (an increase of 157 and 233 AU/mL) maintained BTKi therapy during booster vaccination. While patients that did not respond to booster vaccination were maintained on BTKi therapy, one exception (patient #10) discontinued BTKi therapy at least 5 months before the booster vaccination but also had prior therapy with obinutuzumab. These data suggest that BTKi therapy can interfere with a response to booster vaccination.

In this small cohort, the immunogenicity of booster vaccination did not appear to be affected by disease type, vaccine type (BNT162b2, mRNA-1273, or Ad26.COV2.S), vaccination pairing (homologous or heterologous), or other malignancy-target therapies (intravenous immunoglobulin, chemotherapy, or hematopoietic stem cell transplantation). However, this cohort was likely not powered to detect differences between these subgroupings.

This limited observational study shows that 55% (21/38) of patients with B cell malignancies who failed to make anti-S antibodies after full SAR-CoV-2 vaccines seroconverted after booster vaccination. The inability to make anti-S antibodies to the booster vaccination was correlated with anti-CD20 antibody therapy, particularly in the past 6 months prior to vaccination. It is encouraging that 7 patients (#19, #20, #24, #30, #31, #41, and #42) maintained on a BTKi seroconverted or experienced sero-elevation after booster vaccination and is consistent with a previous report on one patient (Hill et al., 2021).

There are important limitations of this study. First, the treatment and disease were reported by the patient. We are currently obtaining electronic health care records to verify these reports, which will allow us to provide clarity on exactly when treatments occurred and what the sequence of treatments was. Second, larger studies, especially in well-controlled clinical trials in patients with hematologic malignancies, are needed (two are already underway) to verify these results and understand if and when booster vaccines are most likely to benefit patients on B cell-suppressive therapies. Third, we did not measure neutralizing antibody responses, particularly to the delta variant, B cell memory, or T cell responses.

We conclude that some patients with hematologic malignancies who are seronegative after a full course of vaccination may benefit from a booster. However, regulators, patients, and health care providers should be aware that a sizeable subset of patients with blood cancer may remain at risk of breakthrough COVID-19 infections after full vaccination followed by booster vaccination.

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.ccell.2021.09.001.

ACKNOWLEDGMENTS

This study was supported by the Leukemia & Lymphoma Society. We thank our generous donors and patients who have participated in the LLS National Registry, a project of the Michael J. Gaill Data Collective. We thank Citizen and LabCorp for their collaboration in this effort and Brian Chadwick, Neil Kay, Renu Jain, and Jun Xu for their contribution to this research effort. We especially thank the patient participants.

REFERENCES

Bakouny, Z., Hawley, J.E., Choueiri, T.K., Peters, S., Rini, B.I., Warner, J.L., and Painter, C.A. (2020). COVID-19 and cancer: current challenges and perspectives. Cancer Cell 38, 629–646. https://doi.org/10.1016/j.ccell.2020.09.018.

Corey, L., Beyrer, C., Cohen, M.S., Michael, N.L., Bedford, T., and Rolland, M. (2021). SARS-CoV-2 variants in patients with immunosuppression. N. Engl. J. Med. 385, 562–566. https://doi.org/10.1056/NEJMc2104756.

Gilbert, P.B., Montefiori, D.C., McDermott, A., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchnes, C.R., Martins, K., Jayashankar, L., et al. (2021). Immune correlates of analysis of the mRNA-1273 vaccine efficacy trial. MedRxiv. https://doi.org/10.1101/2021.08.09.21261290.

Greenberger, L.M., Saltzman, L.A., Seneff, J.W., Johnson, P.W., DeGennaro, L.J., and Nichols, G.L. (2021). Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell 39, 1031–1033. https://doi.org/10.1016/j.ccell.2021.07.012.

Griffiths, E.A., and Segal, B.H. (2021). Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution. Cancer Cell 39, 1045–1047. https://doi.org/10.1016/j.ccell.2021.07.001.

Hill, V.G., Ferreira, V.H., Ku, T., Ierullo, M., Majchrzak-Kita, B., Chaparro, C., Selzner, N., Schiff, J., McDonald, M., Tomlinson, G., et al. (2021). Randomized trial of a third Dose of mRNA-1273 vaccine in transplant recipients.
Hill, J.A., Ujjani, C.S., Greninger, A.L., Shadman, M., and Gopal, A.K. (2021). Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient. Cancer Cell 39, 1037–1038. https://doi.org/10.1016/j.ccell.2021.06.015.

McLaughlin, P., Grillo-Lozano, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., et al. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825–2833. https://doi.org/10.1200/JCO.1998.16.8.2825.

Resman Rus, K., Korva, M., Knap, N., Avsic Zupanc, T., and Poljak, M. (2021). Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. J. Clin. Virol. 139, 104820.

Vijenthira, A., Gong, I.Y., Fox, T.A., Booth, S., Cook, G., Fattizzo, B., Martin-Moro, F., Razanamahery, J., Riches, J.C., Zwicker, J., et al. (2020). Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136, 2881–2892. https://doi.org/10.1182/blood.2020008824.